Fundación Hospital Alcorcón -ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2023

  1. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

2022

  1. SEA 2022 Standards for Global Control of Cardiovascular Risk

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179

2020

  1. Immunotherapy moves to the early-stage setting in non-small cell lung cancer: Emerging evidence and the role of biomarkers

    Cancers, Vol. 12, Núm. 11, pp. 1-21

2019

  1. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

    Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966

  2. Standards for global cardiovascular risk management arteriosclerosis

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, pp. 1-43

2016

  1. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial

    Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899

  2. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

    Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84

2015

  1. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 7, pp. 398-403

2014

  1. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?

    Blood, Vol. 124, Núm. 12, pp. 1887-1893

2012

  1. Abrogation of RUNX1 gene expression in de novo myelodysplastic syndrome with t(4;21)(q21;q22)

    Haematologica, Vol. 97, Núm. 4, pp. 534-537

2011

  1. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: Toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03)

    Leukemia and Lymphoma, Vol. 52, Núm. 3, pp. 409-416

  2. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

    Blood, Vol. 118, Núm. 17, pp. 4547-4553

2010

  1. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial

    The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941

2009

  1. Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide

    Leukemia and Lymphoma, Vol. 50, Núm. 8, pp. 1283-1289

2007

  1. Haemodynamically unstable pulmonary embolism in the RIETE Registry: Systolic blood pressure or shock index?

    European Respiratory Journal, Vol. 30, Núm. 6, pp. 1111-1116

2004

  1. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry

    Journal of Thrombosis and Haemostasis, Vol. 2, Núm. 11, pp. 1892-1898